山东医药2012，Vol.52Issue(1)：7-9,3.
自体CIK细胞及DC细胞联合索拉非尼治疗转移性肾癌的疗效与安全性
Efficacy and safety of autologous DC and CIK cells combined Sorafenib in the treatment of metastatic renal cell carcinoma
摘要
Abstract
objective To observe the efficacy and side effects of autologous cytokine-induced killer cells ( CIK cells) and dendritic cells (DC) and Sorafenib in the treatment of metastatic renal cell carcinoma ( mRCC). Methods DC and CIK cells were amplified in peripheral blood. Flow cytometry was used to detect CIK, DC-CIK phenotype, and then taking intravenous transfusion method to treat the mRCC patients with autologous CIK, DC and Sorafenib. Results In 26 cases of patients, there were one patient with complete remission, 4 ones with partial remission, 17 ones with stability, 4 ones with disease progression. The rate of disease control is 72. 7% , and the objective effective power is 19. 2%. Median survival time was 25 months, and the lack of progress in time(mPFS) was 14 months. Main side effects were rash, diarrhea, fever, fatigue, flu-like symptoms, anorexia, reduced body mass, and neutrocytopenia, etc. Referenced to the risk factors for prognosis of layered model MSKCC score, RR in the low risk of group was higher than that in the high risk group ( P < 0.05). The MST among low, medium and high risk groups had significant differences(P = 0.000). Conclusion Autologous DC and CIK cells combined with Sorafenib in treating mRCC patients has a acceptable curative effect, and tolerated side effects.关键词
肾肿瘤/索拉非尼/杀伤细胞/树突细胞/免疫疗法Key words
kidney medulla/sorafeni/kill cells/dendritic cells/adoptive immunotherapy分类
医药卫生引用本文复制引用
李建旺,黄春珍,李建华,彭大为..自体CIK细胞及DC细胞联合索拉非尼治疗转移性肾癌的疗效与安全性[J].山东医药,2012,52(1):7-9,3.基金项目
海南省卫生厅医学科研立项课题(2010-SWY-11-056). （2010-SWY-11-056）
